Literature DB >> 28981975

Lung function improvement and airways inflammation reduction in asthmatic children after a rehabilitation program at moderate altitude.

Eugen Bersuch1,2, Florian Gräf1,3, Ellen D Renner1,4,5, Andreas Jung4,6, Claudia Traidl-Hoffmann1,5, Roger Lauener1,7, Caroline Roduit1,6.   

Abstract

BACKGROUND: Rehabilitational programs at moderate altitude (1500-2500 m) showed improvement of lung function and reduction in airways inflammation in asthmatic adults. Allergen avoidance was postulated as the major cause of these improvements.
METHODS: Spirometries of 344 and fractional exhaled nitric oxide measurements (FeNO) of 124 asthmatic children and adolescents, staying in a rehabilitation hospital in Davos (1590 m) with at least 14 days between admission and discharge, were analyzed in association with atopic sensitization (skin-prick testing and/or specific IgE), level of asthma control, and inhalative corticosteroid (ICS) dose.
RESULTS: Pulmonary conditions improved significantly on average during the sojourn. Uncontrolled asthmatics benefited most with an absolute increase in predicted FEV1 , MEF25 , and MEF75 of 7.7%, 9.9%, and 12.7%, respectively (P < .001). FeNO decreased by 36.9 ppb for uncontrolled, by 26.9 ppb for partly controlled, and by 11.8 ppb for controlled asthmatics. In uncontrolled subjects, pulmonary improvement was comparable between patients with and without house dust mites (HDM) sensitization. Pulmonary improvements of pollen-sensitized patients were not dependent on the season of the sojourn. For the group with constant ICS level, the absolute increase in FEV1 was 4.9% (P < .001) with a FeNO decreased by 32.7 ppb (P < .001). When the ICS dose was elevated by one GINA level, the absolute increase in FEV1 was slightly higher (6.6%, P < .001), with a FeNO decrease of 31.4 ppb (P < .001).
CONCLUSION: Inpatient rehabilitation at moderate altitude improved pulmonary conditions in asthmatic children and adolescents independent of sensitization status to HDM or pollen. A positive effect was also observed in patients without change in medication.
© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  Davos; Forced expiratory volume in 1 second; Fractional exhaled nitric oxide; adolescents; asthma; children; inflammation; pulmonary function; rehabilitation

Mesh:

Substances:

Year:  2017        PMID: 28981975     DOI: 10.1111/pai.12808

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  5 in total

Review 1.  Underlying lung disease and exposure to terrestrial moderate and high altitude: personalised risk assessment.

Authors:  Kirsten Holthof; Pierre-Olivier Bridevaux; Isabelle Frésard
Journal:  BMC Pulm Med       Date:  2022-05-09       Impact factor: 3.320

Review 2.  Highlights and recent developments in airway diseases in EAACI journals (2017).

Authors:  J Bousquet; C A Akdis; C Grattan; P A Eigenmann; K Hoffmann-Sommergruber; P W Hellings; I Agache
Journal:  Clin Transl Allergy       Date:  2018-11-27       Impact factor: 5.871

3.  A positive effect of a short period stay in Alpine environment on lung function in asthmatic children.

Authors:  Annalisa Cogo; Michele Piazza; Silvia Costella; Massimiliano Appodia; Raffaele Aralla; Stefania Zanconato; Silvia Carraro; Giorgio Piacentini
Journal:  Pediatr Pulmonol       Date:  2022-06-06

4.  Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough: a meta-analysis.

Authors:  Pasquale Ambrosino; Mariasofia Accardo; Marco Mosella; Antimo Papa; Salvatore Fuschillo; Giorgio Alfredo Spedicato; Andrea Motta; Mauro Maniscalco
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

5.  Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper.

Authors:  Karin B Fieten; Marieke T Drijver-Messelink; Annalisa Cogo; Denis Charpin; Milena Sokolowska; Ioana Agache; Luís Manuel Taborda-Barata; Ibon Eguiluz-Gracia; Gerrit J Braunstahl; Sven F Seys; Maarten van den Berge; Konrad E Bloch; Silvia Ulrich; Carlos Cardoso-Vigueros; Jasper H Kappen; Anneke Ten Brinke; Markus Koch; Claudia Traidl-Hoffmann; Pedro da Mata; David J Prins; Suzanne G M A Pasmans; Sarah Bendien; Maia Rukhadze; Mohamed H Shamji; Mariana Couto; Hanneke Oude Elberink; Diego G Peroni; Giorgio Piacentini; Els J M Weersink; Matteo Bonini; Lucia H M Rijssenbeek-Nouwens; Cezmi A Akdis
Journal:  Allergy       Date:  2022-02-15       Impact factor: 14.710

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.